Login to Your Account



European Society for Medical Oncology

Synta Sizzles on Ganetespib Phase IIb Data in Lung Cancer

By Marie Powers
Staff Writer

Tuesday, October 2, 2012
Analysts were exuberant after Synta Pharmaceuticals Corp. disclosed results Saturday from an interim analysis of the Phase IIb portion of its GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) trial of ganetespib, the company's lead heat-shock protein 90 (Hsp90) inhibitor, as second-line treatment in advanced non-small-cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription